A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs FPA 150 (Primary)
- Indications Advanced breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- Sponsors Five Prime Therapeutics
- 16 Oct 2018 According to the Five Prime Therapeutics media release, company Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
- 28 Mar 2018 According to a Five Prime Therapeutics media release, dosing of patients have been started.
- 28 Mar 2018 Status changed from planning to recruiting, according to a Five Prime Therapeutics media release.